EnsoData

About EnsoData

EnsoData is a healthcare technology firm specializing in the application of artificial intelligence to analyze waveform data for medical diagnostics, with a primary focus on sleep medicine. The company was founded in 2015 by Chris Fernandez, Sam Rusk, and Nick Glattard, who met at the University of Wisconsin-Madison, sharing a common interest in machine learning and its potential to solve complex healthcare problems. Their journey began by tackling the time-consuming and inconsistent process of manually scoring sleep studies.

The company's business model is centered on a Software-as-a-Service (SaaS) platform provided to healthcare organizations. Clients include sleep clinics, hospitals, academic medical centers, and home sleep testing providers. EnsoData generates revenue by offering its AI-powered software solutions to these providers, which helps automate the analysis of sleep studies, thereby increasing efficiency and allowing clinicians to focus more on patient care.

EnsoData's flagship product, EnsoSleep, received its initial FDA 510(k) clearance in 2017 for analyzing in-lab sleep studies. This was a significant milestone, establishing the company as an early player in FDA-cleared AI for sleep medicine. The technology works by analyzing billions of data points from sensors that measure biological signals like brain waves (EEG) and heartbeats (ECG) to identify patterns indicative of sleep disorders. In 2021, EnsoSleep's FDA clearance was expanded to include home sleep studies, a viewing and editing platform, and total sleep time measurement. A further advancement came in February 2024 with the FDA clearance of EnsoSleep PPG. This software leverages photoplethysmogram (PPG) signals from widely available pulse oximeters, turning these cost-effective wearable devices into diagnostic tools for sleep apnea. The platform is designed for interoperability, integrating with existing sleep lab management software and electronic health records to streamline workflows.

The company's founding team brings a strong technical background to the firm. Chris Fernandez, Sam Rusk, and Nick Glattard all have backgrounds in engineering and machine learning from the University of Wisconsin-Madison. Fernandez now serves as Executive Chairman & Chief Research Officer, Rusk is the Chief AI Officer, and Glattard is the Chief Technology Officer. Their collective expertise has driven the development of EnsoData's Waveform AI. The company has successfully raised over $50 million in funding through multiple rounds, including a $20 million Series B in June 2025, to fuel its growth, expand its commercial team, and pursue further research and development into other areas of healthcare like cardiology and neurology.